Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Completed · Phase 3

Conditions studied: Orthomyxoviridae Infection, Influenza, Myxovirus Infection

In brief

This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route. Primary Objective: * To demonstrate lot consistency of the Fluzone ID manufacturing process. * To provide information concerning the immune response of Fluzone ID. Secondary Objectives: Safety * To describe the safety profile of subjects who receive of Fluzone ID.

Key facts

Study ID

NCT00772109

Run by

Sanofi Pasteur, a Sanofi Company

People needed

4292

Starts

2008-10-01

Expected to finish

2009-07-01

Last updated by the study team

2016-04-14

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 18 to 64 years on the day of vaccination.
• Informed consent form signed and dated.
• Able to attend all scheduled visits and to comply with all trial procedures.
• For women of child bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 4 weeks after vaccination.

You may not qualify if…

• Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.
• For a woman of child-bearing potential: known pregnancy or positive serum/urine pregnancy test.
• Breast-feeding woman.
• Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the four weeks preceding the trial vaccination.
• Planned participation in another clinical trial during the present trial period.
• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
• Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.
• Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures.
• Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.
• Receipt of any vaccination in the 4 weeks preceding the trial vaccination.
• Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
• Previous vaccination against influenza in the past 6 months with the trial vaccine or another vaccine.
• Thrombocytopenia or bleeding disorder in the 3 weeks preceding inclusion.
• Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
• Neoplastic disease or any hematologic malignancy, (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, and subjects who have a history of neoplastic disease and who have been disease free for >=5 years).
• Personal or family history of Guillain-Barré Syndrome.

Where it is running

• Study site — Hoover, Alabama, United States
• Study site — Huntsville, Alabama, United States
• Study site — Mobile, Alabama, United States
• Study site — Chandler, Arizona, United States
• Study site — Mesa, Arizona, United States
• Study site — Phoenix, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Fountain Valley, California, United States
• Study site — San Diego, California, United States
• Study site — Milford, Connecticut, United States
• Study site — Melbourne, Florida, United States
• Study site — Pembroke Pines, Florida, United States
• Study site — Pinellas Park, Florida, United States
• Study site — Boise, Idaho, United States
• Study site — Chicago, Illinois, United States
• Study site — Iowa City, Iowa, United States
• Study site — Wichita, Kansas, United States
• Study site — Lexington, Kentucky, United States
• Study site — Madisonville, Kentucky, United States
• Study site — Rockville, Maryland, United States
• Study site — Kansas City, Missouri, United States
• Study site — Springfield, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Binghamton, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.